Drug composition for angiogenesis therapy

Abstract

The present invention relates to: drug compositions of angiogenesis therapy that contains gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I 2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI 2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

1 . A drug composition of angiogenesis therapy used for treatment and prevention of peripheral arterial disease comprising;
 an active component, an adeno-associated virus (AAA) inserted with a PGIS gene producing a prostaglandin I2 (PGI2) which induces one or more of the activities selected from the group consisting of vasodialation, anti-platelet aggregation and angiogenesis.   
     
     
         2 . The drug composition of angiogenesis therapy according to  claim 1 , wherein the adeno-associated virus (AAV) is further inserted with a gene coding for an angiogenesis factor. 
     
     
         3 . A drug composition of angiogenesis therapy used for treatment and prevention of peripheral arterial disease comprising;
 an active component, a first adeno-associated virus (AAV) inserted with a PGIS gene producing a prostaglandin I2 (PGI2) which induces one or more of the activities selected from the group consisting of vasodialation, anti-platelet aggregation and angiogenesis,   and a second adeno-associated virus (AAV) inserted with a gene coding for an angiogenesis factor.   
     
     
         4 . The drug composition of angiogenesis therapy according to any of  claims 1  to  3 , wherein the adeno-associated virus (AAV) is of the type selected from the group consisting of type 1, 2, 5 and 8. 
     
     
         5 . The drug composition of angiogenesis therapy according to any of  claims 1  to  3 , wherein the adeno-associated virus (AAV) is of the type selected from the group consisting of type 1 and 2. 
     
     
         6 . The drug composition of angiogenesis therapy according to any of  claims 2  to  3 , wherein the gene coding for an angiogenesis factor is a gene coding for a material selected from the group consisting of a protein, a peptide and a part thereof capable of inducing angiogenesis. 
     
     
         7 . The drug composition of angiogenesis therapy according to any of  claims 1 , wherein the gene coding for an angiogenesis factor is a vascular endotherial growth factor (VEGF). 
     
     
         8 . The drug composition of angiogenesis therapy according to any of  claims 1 , further comprising a pharmaceutically permissible carrier containing the adeno-associated virus (AVV).